SpliceBio Secures $135M in Series B to Accelerate Next-Generation Gene Therapies Through Protein Splicing Breakthroughs

SpliceBio, a pioneering biotechnology company, is thrilled to announce that it has successfully raised $135,000,000 in its latest funding round. This significant investment is a testament to the strong belief and confidence that leading investors—including UCB Ventures, Ysios Capital, NEA, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners—have in SpliceBio's cutting-edge approach to gene therapy. The funds will enable the company to further harness the potential of Protein Splicing, a revolutionary mechanism that underpins the development of next-generation gene therapies, and expand its proprietary platform developed in the renowned Muir Lab at Princeton University. SpliceBio is at the forefront of a transformative era where innovative protein engineering and intein research meet clinical application. The company’s co-founders, who bring more than 20 years of pioneering research from the realms of protein engineering, have crafted a robust foundation that is set to accelerate advancements in gene therapy development. With the recent influx of capital, SpliceBio is poised to scale its research and development efforts, streamline its path towards clinical trials, and ultimately deliver life-changing treatments to patients suffering from a variety of genetic disorders. The new funding will drive critical investments in expanding laboratory operations, bolstering the company’s talent pool, and enhancing its technology platform to ensure seamless transition from experimental innovation to scalable, real-world applications. As SpliceBio continues to push the boundaries of what is possible in biotechnology, this milestone funding round marks not just a financial achievement, but a bold step forward in transforming the landscape of gene therapies and improving patient outcomes worldwide.